ML-792

Also Known As:

((1R,2S,4R)-4-((5-(1-(3-bromobenzyl)-1H-pyrazole-3-carbonyl)pyrimidin-4-yl)amino)-2-hydroxycyclopentyl)methyl sulfamate; sulfamic acid, ((1R,2S,4R)-4-((5-((1-((3-bromophenyl)methyl)-1H-pyrazol-3-yl)carbonyl)-4-pyrimidinyl)amino)-2-hydroxycyclopentyl)methyl ester

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Barefield, James: 1 article (01/2021)
2.	Barnhill, Alex: 1 article (01/2021)
3.	Bentz, Gretchen L: 1 article (01/2021)
4.	Garcia, Peter: 1 article (01/2021)
5.	Harrod, Abigail: 1 article (01/2021)
6.	Jenkins, Jessica: 1 article (01/2021)
7.	Jha, Shruti: 1 article (01/2021)
8.	Lee, Holden: 1 article (01/2021)
9.	Lowrey, Angela J: 1 article (01/2021)
10.	Mckinnon, Ashton: 1 article (01/2021)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2021 - "Together, these findings suggest that ML-792 may be a potential therapeutic drug to treat EBV-associated lymphoid malignancies by targeting oncogenesis and the EBV life-cycle." 11/01/2017 - "ML-792 selectively blocks SAE enzyme activity and total SUMOylation, thus decreasing cancer cell proliferation. " 01/01/2020 - "This review summarizes the normal roles of the enzymes involved in the SUMOcatalytic cycle, their misbalanced regulation leading to tumorigenesis and nearly all the potent inhibitors identified to date, while after detailed studied it was observed that ML-792 could be a promising inhibitor in treating cancers by inhibiting Sumoylation enzymes."
2.	Carcinogenesis 01/01/2021 - "Together, these findings suggest that ML-792 may be a potential therapeutic drug to treat EBV-associated lymphoid malignancies by targeting oncogenesis and the EBV life-cycle." 01/01/2020 - "This review summarizes the normal roles of the enzymes involved in the SUMOcatalytic cycle, their misbalanced regulation leading to tumorigenesis and nearly all the potent inhibitors identified to date, while after detailed studied it was observed that ML-792 could be a promising inhibitor in treating cancers by inhibiting Sumoylation enzymes."
3.	Epstein-Barr Virus Infections 01/01/2021 - "Effects of targeting sumoylation processes during latent and induced Epstein-Barr virus infections using the small molecule inhibitor ML-792."
4.	Infections 01/01/2021 - "Finally, while higher concentrations of ML-792 were sufficient to induce low levels EBV spontaneous reactivation, they decreased the production of new infectious virus following an induced reactivation and the infection of new cells, suggesting that ML-792 has anti-viral potential. "
5.	Nasopharyngeal Carcinoma 01/01/2021 - "Results showed that ML-792 inhibited sumoylation processes in multiple EBV-positive B cell lines and EBV-positive nasopharyngeal carcinoma cell lines but not in their EBV-negative counterparts. "

Related Drugs and Biologics

1.	Enzymes